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Abstract: 
Objective: The study of mycobacterium susceptibility to the combined application of anti-tuberculosis drugs and "Alcohol 
Balsam" based on beekeeping products. 
Methods: The anti-tuberculosis activity of ATD (anti-tuberculosis drugs) and dietary supplements "Alcohol Balsam" 
combination was studied in in vitro experiment in 2016. The results of swabs microscopy were assessed by the amount of 
bacteria within microsopic view and intensity of the "curve". The growth of MBT (mycobacterium tuberculosis) surface 
culture in test tubes was determined visually according to the number of colonies on the surface of the breeding ground. The 
research scientists tested 11, 12, 13 and 14 days’ drug effects on mycobacterium culture.  
Findings: In case of the main anti-tuberculosis drugs and "Alcohol Balsam" combined application, the growth of drug-
sensitive and multidrug-resistant strains of tuberculosis bacterium is suppressed by 100% in earlier phases compared to the 
anti-tuberculosis drug application alone.  
Conclusions: Various dilutions of ‘Alcohol balsam’ based on beekeeping products being added to the breeding ground of 
the first and second line anti-tuberculosis drugs increase their drugs bactericidal effects. Moreover, in earlier phases they 
suppress the growth of drug-sensitive and multidrug-resistant strains of tuberculosis mycobacterium in 100 % of cases. 
Thus, the efficacy and expediency of Galleria mellonella larvae based drugs application for human tuberculosis prevention 
and comprehensive treatment have been proved. 
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INTRODUCTION: 
One of the most serious issues that medicine has 
dealt with for a considerable course of time is the 
treatment and prevention of human tuberculosis. 
Today, when modern science has achieved 
significant results in various fields, tuberculosis 
(TB) is still a great problem [40, 1]. 
Despite the considerable progress in tuberculosis 
reduction in the world, for several decades 
Kazakhstan has been on the list of countries with 
the highest disease level, including multidrug-
resistant and extensively drug-resistant 
tuberculosis. It is necessary to point out that 
tuberculosis is mostly common among the working 
age population which includes people aged 18 to 44 
years old, more than half of the patients are less 
than 34 years old [11]. 
This situation results from the high resistance of 
mycobacterium tuberculosis to drugs, with the 
assortment of anti-tuberculosis drugs (ATD) 
remaining unchanged for considerable time; and 
being practically not replenished. The current anti-
tuberculosis drugs affect the human organism very 
negatively, reduce the immune system and 
contribute to the malfunction of all organs and 
systems. [16]. 
It is possible to increase the effectiveness of 
treating tuberculosis patients in various locations 
by the combined use of chemotherapeutic and other 
biologically active drugs and/or addition of raw 
materials with the purpose of reducing endogenous 
intoxication, treating undesirable side effects 
caused by TB drugs [16], normalizing metabolism 
and accelerating recovery processes [2,]. 
Drugs that contribute to the immune system 
normalization and have a wide range of therapeutic 
effects should be searched for among the new 
classes of biologically active raw materials. Having 
stated that, it is necessary to point out that the 
research scientists of this article develop drugs 
based on the greater wax moth larvae, propolis and 
honey. 
Galleria mellonella is a pest of honey bees [22]. 
Feeding with honeycombs of honey and bee pollen, 
Galleria mellonella larvae (GML) contains all the 
biologically active substances that beekeeping 
products are made of. According to a number of 
clinical studies, GML extract has a therapeutic 
effect in diseases of various aetiology and 
localization, including respiratory diseases such as 
acute respiratory infections, pneumonia, bronchitis, 
and, most importantly, in case of TB [22]. 
Tuberculosis causative agent protective shell, that 
makes the disease highly resistant to many ATD, 
contains waxlike substances, which are the main 
element of GML nutrition. G.mellonella larvae 
absorbs up to 50% of products that wax is made of. 
They can digest the myristyl ether of palmitic acid, 
which is the reason why they have such specific 
lipases in contrast to other insects [19, 21]. 
When studying the properties of G.Mellonella 
extract for the purpose of anti-tuberculosis activity 
factor identification, it was found that the lipolytic 
and antibacterial properties are provided by the 
protein component of the extract, including lipases, 
capable of destroying certain vital lipids for 
mycobacterium and other species-specific lipid 
layer molecules of the cell wall [15]. 
GML drugs tuberculostatic effect was defined. 
Experimental guinea pigs were intraperitoneally 
administered with a single dose of 100,000,000 
bacteria incubated at 37 °C for 18 hours in 
unprocessed lipase and/or esterase preparations 
isolated from GML and showed significant regress 
of the tuberculosis process. Within seven weeks 
after inoculation, no visible pathology was 
observed, while control animals died in seven 
weeks. However, the preparations did not show any 
bactericidal activity, and experimental guinea pigs 
showed the onset of tuberculosis process at the 
eighth week after the infection [25]. 
Based on the aforementioned information, it is 
concluded that even after a short exposure of GML 
preparations, MBT became avirulent and more 
vulnerable to ATD. 
The relevance of the research is that the combined 
use of ATD and preparations based on GML and 
propolis increases the effectiveness of ATD, 
decreases negative effect on the human body, 
reduces treatment time and cost and therefore can 
be successfully used to solve one of the most 
important problems of medicine - tuberculosis 
treatment. 
The main goal of the research work is to find out 
the mycobacterium drug susceptibility to the 
combined use of ATD and alcohol balsam that is, 
define the minimum inhibitory concentration of 
balsam (MIC) causing partial (+) or complete (0) 
growth suppression of the standard MBT dose at 
earlier times. 
 
 MATERIALS AND METHODS: 
Within the framework of previous scientific 
research conducted in 2015-2017, "Alcohol 
balsam" and "Honey balsam" preparations were 
developed on the base of non-traditional 
beekeeping products with the aim of prevention 
and comprehensive treatment of human 
tuberculosis. 
The research scientists tested physical and chemical 
parameters of preparations, and evaluated the 
safety and quality of products in the Academy of 
Nutrition of the Republic of Kazakhstan (Almaty). 
Company Standards have been developed and 
approved for the products [20], applications for 
inventions have been filled. 
In 2016 there was an in vitro experiment to study 
the combined antitubercolousis activity of the 
"Alcohol Balsam" based on beekeeping products 
(AB), with the ethyl alcohol contain not exceeding 
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20%, and ADT towards the museum (H37RV) and 
multidrug-resistant (MDR) strain of 
Mycobacterium tuberculosis. 
The experiment was carried out based in reference 
laboratory of the National Center for Tuberculosis 
Problems (city of Almaty) in accordance with the 
Methodological Guidelines for the antituberculosis 
activity of the pharmacological substances, the 
bacteriostatic and bactericidal activity of the new 
compounds in vitro experiments studying [17]. 
The following items were used in the experiment of 
mycobacterium drug susceptibility: 
1.  test preparation "Alcohol Balsam" based 
on  beekeeping products (AB) in dilutions: 100; 20; 
10; 5; 2.5; 1.25; 0.625 μg/ml of active substance. 
Before serial dilution, the test preparation for its 
sterility was passed through an ultra-thin bacterial 
filter Millex CA with a pore size of 0.22μm, 
diameter of 33mm; 
2. first series ATD -  rifampicin (R) 40 
μg/ml, isoniazid (H) 1 μg/ml; 
3. reserve series ATD - amikacin (Am) 20 
μg/ml, moxifloxacin (Mfl) 20 μg/ml. 
The bactericidal and bacteriostatic activity 
of the preparations was determined in vitro on the 
museum strain H37Rv and multidrug-resistant wild 
strain (MDR) (resistant to rifampicin and isoniazid) 
isolated from the patients. 
4 groups were involved in the experiment. 
Each group contained test tubes with Shkolnikov 
breeding ground, various preparations and different 
periods of drugs exposure. 
1 test group - AB + 0.2 ml of H37RV strain 
+ H + R 
2 test group - AB + 0.2 ml MDR strain + 
Mfx + Am 
3 group - control - 0.2 ml of H37RV strain + 
H + R 
4 group - control - 0.2 ml MDR strain + Mfx 
+ Am 
Schkolnikov breeding ground without preparations 
was used as control in all the experiments. 
Each group contains 8 test tubes, one of which (No. 
1) is the control one (without preparations), and the 
other 7 test tubes are with preparations in the 
indicated dilutions (Table 1). 
5 durations of drug exposure to MBT were 
studied. Test tubes were incubated for 10; 11; 12; 
13; 14 days at 37°C. On expiration of the 
incubation period, the precipitates on a liquid 
medium were washed with physiological saline. 
Swabs were made of the resulting suspension and 
stained according to Ziehl-Neelsen, then the test 
tubes for 0.2ml were inoculated with a dense egg 
medium of Levenshtein-Jensen (in duplicate). 
The result of swabs microscopy was assessed by 
the amount of MBT visible in the microscopic field 
of view and by the intensity of the "curve" 
according to the following scheme: 
no MB – within 100 microscopic fields of 
view     
  - 
1-9 MB – within 100 microscopic fields of 
view     
 ± 
10-100 MB – within 100 microscopic fields 
of view     
 + 
1-9 MB – within 1 microscopic field of view
     
  ++ 
10 and more within1 microscopic field of 
view , "curve"  +++ 
 
The results of culture studies were assessed 
visually according to the number of colonies on the 
surface of the culture medium after 2.5 months of 
cultivation in a thermostat at 37°C according to the 
scheme 
no colonies on the swarm  - 
a single colony, up to 20  + 
colonies from 20 to 100  ++ 
more than 100 colonies  +++ 
 
Table 1: Experiment scheme to determine the bactericidal activity of the combined use of ATD and 
Alcohol Balsam. 
Group/ 
strain MBT 
No of test tube and preparation  
1 2 3 4 5 6 7 8 
1 / Н37RV - 
СБ 100 
μg/ml + Н+R 
СБ  20 
μg/ml + 
Н+R 
СБ  10 
μg/ml + 
Н+R 
СБ 5 μg/ml 
+ Н+R 
СБ 2,5 
μg/ml + 
Н+R 
СБ  1,25 
μg/ml + Н+R 
СБ 0,625 
μg/ml + Н+R 
2 / 
MDR 
- 
СБ  100 
μg/ml + 
Мfx+ 
Am 
СБ  20 
μg/ml + 
Мfx+ 
Am 
СБ  10 
μg/ml + 
Мfx+ 
Am 
СБ 5 μg/ml 
+ Мfx+ 
Am 
СБ 2,5 
μg/ml + 
Мfx+ 
Am 
СБ  1,25 
μg/ml + 
Мfx+ 
Am 
СБ 0,625 
μg/ml + 
Мfx+ 
Am 
3 / Н37RV - Н+R Н+R Н+R Н+R Н+R Н+R Н+R 
4 /  
MDR 
- 
Мfx+ 
Am 
Мfx+ 
Am 
Мfx+ 
Am 
Мfx+ 
Am 
Мfx+ 
Am 
Мfx+ 
Am 
Мfx+ 
Am 
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Literature Review 
Despite all the achievements of modern medicine, 
tuberculosis is still one of the most serious diseases 
and the global problem of public health. 
According to WHO (World Health Organization), 
10.4 million new cases of the disease were 
registered worldwide in 2015 [42], 1.2 million 
(11%) of all the new patients were HIV-infected, 
about 480 000 new cases of tuberculosis with 
MDR. There were 1.8 million registered deaths 
caused by TB, 0.4 million of which were HIV-
infected people [41,36]. 
In Kazakhstan, for the period of 2000-2015, the 
record of TB cases declined by 6% [35], MDR-TB 
cases among new tuberculosis patients by 2% [41], 
mortality by 72.8% [16].  
Despite the obvious tendency, the level of 
morbidity and mortality caused by TB is still high 
[4, p. 283]. Kazakhstan is on the list of the top five 
countries with the largest number of new TB cases 
in 2015: Russia (115,000 - 0.08%), Ukraine 
(41,000), Uzbekistan (24,000), Kazakhstan  
(16,000 - 0.09%) and Romania (16,000) [35]. The 
level of new TB cases in places of detention in the 
Republic of Kazakhstan exceeded 1,000 cases per 
100,000 arrested people (915 per 100,000 
population were registered in prisons of European 
Region WHO) [35]. 
At the same time, the analysis of the 
epidemiological situation of TB in the world 
showed a tendency of MDR-TB morbidity increase 
[5]. According to WHO data, over the last five 
years, Kazakhstan, Russia, Estonia, Uzbekistan, 
Ukraine, Kyrgyzstan and Belarus have entered the 
list of countries with the highest number of MDR 
tuberculosis patients among the newly diagnosed 
(19.3-34.1%) [ 40, 25, 32]. TB is widespread and 
exceeds the WHO recommended incidence 
threshold in these countries up to 10 times [1, p. 
459; 47, p. 7]. 
Infiltrative (79.3%) and focal TB (10.9%), 
exudative pleurisy (6.6%) are most common cases 
in the Republic of Kazakhstan. Also up to 40% 
cases of bacterial excretion were found in the 
patients examined [11]. Mostly, these are people of 
high-risk groups (alcoholics, smokers, HIV-
infected, migrants, prisoners and those discharged 
from prison) [16]. 
Concerning gender distribution, the TB cases 
among children younger than 14 years old make up 
45% in boys and 55% in girls. Among patients 
older than 15 years old, the incidence of men is 1.5 
times higher than that of women. The most 
frequent cases are spread among women who are 
25-34 years old (119 cases per 100,000), men who 
are 35-44 years old (180 cases per 100,000) [40, p. 
175], which is also confirmed by Kazakhstani 
scientists [11]. 
One TB patient treatment requires more than 1 
million KZT every year. Despite the availability of 
free ATD, due to temporary work incapacity, 
productivity (up to 37%)   and incomes (by 10%) of 
TB patients are reduced, moreover,  expenses 
caused by the need of purchasing additional drugs 
and adequate nutrition increase up to 33% [39]. 
For more than three decades, the standard 6-18-
month R-CHOEP is used for TB treatment in the 
world practice. However, existing treatment 
regimens are based on the drugs that have been 
used for more than 40 years [24]. Often, treatment 
is complicated by the emergence of MBT drugs 
resistant that retain the ability to generate and lead 
to disease recurrence [38, 42]. 
Recording and controlling of MDR-TB complexity 
is due to the inadequacy of systematic follow-up 
examinations, lack of clear data on the 
geographical distribution of MDR forms by the 
regions, and also the limited participation of health 
workers, which significantly reduces the detection 
of outbreak hotbeds [16,44]. 
The development, introduction and industrial 
production of new drugs with high bacteriostatic 
and bactericidal MBT activity is a part of the 
tuberculosis infection control WHO programme. 
Currently, research works are conducted in several 
areas: testing of known drugs by composing new 
combinations and treatment regimens based on 
them [34], development of new drugs ATD [9], 
including drugs made of natural raw materials [14], 
and additional physiotherapy procedures. Also, 
another area of research is the usage of drugs [23] 
designed to eliminate intoxication, improve the 
immune system, reduce side effects caused by 
chemotherapy and shorten treatment duration. 
Among the approved antibacterial drugs used from 
1981 to 2010, more than a half (about 65%) were 
natural antimicrobials (including rifampicin and 
aminoglycoside PTP) or made of natural raw 
materials [24].  
For the first time since the introduction of 
rifampicin in the late 1960s, two drugs were 
approved in 2013 and 2014: bedaquiline and 
delamanid for MDR tuberculosis treatment. 
However, the data on toxicity and risk of 
unexplained mortality and other side effects limit 
its use for MDR-TB treatment [31]. 
TB is one of the diseases the course and outcome of 
which is largely determined by the immune status 
of the patients. Pathophysiological disorders caused 
by TB development negatively affect the course of 
the disease and its therapy. The development of 
tuberculosis immunity involves a variety of specific 
and nonspecific factors of body defence. This 
justifies the need to use various preparations in 
combination with etiotropic drugs activating the 
body defence systems and restoring disturbed 
homeostasis. Such a complex treatment can 
increase the effectiveness of therapy several times 
[18]. 
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Therefore, modern phthisiology uses a variety of 
technologies which are mainly focused on TB 
patients treatment optimizing by improving their 
quality of life (adequate nutrition, sanatorium 
treatment), increasing the body natural resistance 
and obtaining the most positive effect in the 
shortest possible time [2]. A variety of preparations 
is available in addition to the main ATD treatment 
in the therapy regimen. These preparations mainly 
have immunomodulating [6], anti-inflammatory, 
antioxidant [3], hepatoprotective and other 
properties. 
Any experimental therapy is aimed at treatment 
period reduction without increasing the rate of 
relapses, the increase of the body resistance and the 
reduction of treatment cost due to a shorter period 
of therapy. 
In the struggle against tuberculosis, one of the 
indispensable factors is the search for new ATD 
that actively and directly affect TB causative agent 
without causing side effects, have a wide range of 
therapeutic effects and contribute to the 
normalization of the immune system. 
However, the complexity of TB effective treatment 
is due to the biological properties of the pathogen. 
It is known that the protective shell of MBT 
contains waxlike substances, which cause its high 
resistance to many ATD. 
Therefore, another area being researched by 
scientists, including the authors of this article, is the 
development of drugs reducing the resistance of 
MBT by destroying and/or changing the structure 
of the protective shell. 
Scientists from the University of Queensland and 
the University of California in San Francisco have 
found a promising new method for TB-causing 
bacteria suppression. The research team headed by 
Professor Paul Ortiz de Montellano in the United 
States of America studied the effect of compounds 
on M.tuberculosis associated with cholesterol. It is 
known that cholesterol affects the TB virulence and 
infectivity. Two analogues of cholesterol with 
truncated, fluorinated side chains were synthesized 
stopping the growth of M.tuberculosis culture, 
since it cannot be used as a source of energy [33]. 
A fundamentally new class of the initial 
biologically active feedstock concerning the 
reduction of MBT resistance is represented by the 
GML. 
Galleria mellonella parasitizes a bee family. This is 
the only insect whose larvae can digest the wax - a 
part of tuberculosis causative agent shell [22].  
GML is known all over the world as an object of 
research. 
The first scientist who started to study Galleria 
mellonella at the end of the 19th century, in search 
of a remedy for TB treatment was I.I. Mechnikov. 
Later Moscow doctor S.A. Mukhin developed 
effective combinations of the extract with the other 
biologically active components and created a 
complex preparation "Vita" on its basis, capable of 
repairing tuberculous caverns in the lungs [12]. 
N.A. Spiridonov developed and patented a method 
for large-scale production of GML active extract 
and studied the chemical composition of the 
extract, identified some active components [19]. 
Currently, GML is used for the production of 
different therapeutic effect drugs in the CIS 
(Commonwealth of Independent States) countries 
[13]. 
GML is primarily used abroad as a model and an 
alternative host for studying of various pathogens 
virulence factor and the immune response of larvae 
infected by bacteria since the GML system is 
functionally analogous to the mammalian immune 
system and possesses both humoral and cellular 
immunity [44]. 
Russian scientist S.I. Metalnikov made similar 
experiments with the TB causative agent in the 
early 20th century. He injected various doses of 
MBT into the larvae body cavity. Infected larvae 
did not die, but continued to grow, turning into an 
adult insect. During the study of GML blood and 
internal organs, it was found out that the 
phagocytes of larvae rapidly captured and digested 
MBT. And even after a large amount of MBT 
administration, they were destroyed in 2-3 days, 
and the infected larvae were perfectly healthy [10]. 
This made it possible to assume that the GML 
drugs have the same properties. 
GML has a broad spectrum of effects. The 
lysozyme and anionic peptide in their hemolymph 
cause the fungistatic and fungicidal activity of 
preparations made of G.mellonella larvae. During 
the experiments, lysozyme inhibited the growth of 
Candida albicans fungus, significantly reducing its 
metabolic activity and causing changes in the 
topography and properties of the cell surface as 
compared to the control cells. A synergistic effect 
of peptide and lysozyme on C. Albicans was also 
found, which determined the important role in the 
early stages of fungus immune response [48]. 
In the development of new antiinfectives in the 
pharmaceutical industry, Antimicrobial proteins 
and peptides (AMP), which are also the humoral 
immune factor providing natural immunity, carry 
an important role. Therefore, antibacterial and 
scientists consider antifungal peptides and insect 
proteins as an alternative to antibiotics. G. 
mellonella serves as a good model for biochemical 
studies. Considering the size of the insect, it is easy 
to obtain hemolymph and other tissues as a source 
of many immunodeficient polypeptides [27]. Thus, 
purified antimicrobial peptide - gloverin was 
isolated from GML, and it showed specific 
antimicrobial activity against two different strains 
of Escherichia coli [49]. 
A resinous substance of a greenish-brown or brown 
colour with a pleasant aroma of poplar buds, honey, 
wax and vanilla, propolis, which is also a part of 
IAJPS 2017, 4 (10), 3678-3688            Natalia Vladimirovna Valitova
 
et al             ISSN 2349-7750 
 w w w . i a j p s . c o m  
 
Page 3683 
the alcohol balsam, is used by bees to maintain 
aseptic conditions in the hive. 
Propolis is a complex mechanical mixture of some 
groups of substances: resin - 50 - 85%, essential 
oils - 1.5 - 4.5%, wax - 12 - 40%, tannins - 4 - 
10.5%, pollen 5 - 11%, mechanical impurities - 5 - 
15%. It also contains vitamins A, C and E [7]. 
Propolis has antifungal, antiinflammatory, 
immunostimulating, regenerative, antioxidant 
[4,46], anesthetic and antitoxic effects. 
Antimicrobial effect of propolis is due to 
flavonoids and benzoic acid [29], which inhibit the 
growth of many microorganisms [37, p. 437; 43, p. 
6]. 
Due to its properties, propolis solution is applied in 
case of the upper respiratory tract disease, 
dentistry, gastrointestinal diseases, arthritis, 
radiation therapy [28], etc. 
The advantage of propolis, compared to the other 
medicinal products, is its harmless effect on the 
body and its possible application as an independent 
therapeutic agent and also in combinations with 
other drugs. 
Based on the aforementioned, preparations or 
biologically active supplements containing extract 
of GML and propolis are promising in the fight 
against tuberculosis. 
 
RESULTS: 
The result of swabs microscopy was assessed by 
the number of mycobacterium within microscopic 
view and the intensity of "obliquity formation" 
under microscopy in accordance with the above 
scheme. 
The expansion of the surface culture of H37RV and 
MDR strain in test tubes was determined visually 
according to the number of colonies on the surface 
of the breeding ground. The results of the 
experiment are presented in Table 2. 
 
 
Table 2: Results of the bactericidal activity of the combined ATD and Alcohol Balsam application. 
 
G
ro
u
p
 
T
es
t 
tu
b
e 
N
o
 
Version 
Results  
microscopy (number of MBT within 
view, intensity of "obliquity 
formation") 
cultural studies (number of colonies 
on the swarm) 
period of incubation, day  period of incubation, day 
10 11 12 13 14 10 11 12 13 14 
1 group 
1 Control (no preparation) 
++ ++ +++ +++ +++ ++ +++ +++ +++ +++ 
2 Н37RV+Н+R + AB 100 μg/ml 0 0 0 0 0 0 0 0 0 0 
3 Н37RV+Н+R + AB 20 μg/ml 0 0 0 0 0 0 0 0 0 0 
4 Н37RV+Н+R + AB 10 μg/ml 0 0 0 0 0 0 0 0 0 0 
5 Н37RV+Н+R + AB 5 μg/ml 0 0 0 0 0 0 0 0 0 0 
6 Н37RV+Н+R + AB 2.5 μg/ml 0 0 0 0 0 0 0 0 0 0 
7 Н37RV+Н+R + AB 1,25 μg/ml 0 0 0 0 0 0 0 0 0 0 
8 Н37RV+Н+R + AB 0,625 μg/ml 0 0 0 0 0 0 0 0 0 0 
2 group 
1 Control (no preparation) ++ ++ ++ ++ ++ ++ ++ +++ ++ ++ 
2 MDR+Мfx+Am + AB  100 μg/ml 0 0 0 0 0 0 0 0 0 0 
3 MDR+Мfx+Am + AB  20 μg/ml 0 0 0 0 0 0 0 0 0 0 
4 MDR+Мfx+Am + AB  10 μg/ml 0 0 0 0 0 0 0 0 0 0 
5 MDR+Мfx+Am + AB  5 μg/ml 0 0 0 0 0 0 0 0 0 0 
6 MDR+Мfx+Am + AB 2,5 μg/ml 0 0 0 0 0 0 0 0 0 0 
7 MDR+Мfx+Am + AB 1,25 μg/ml 0 0 0 0 0 0 0 0 0 0 
8 MDR+Мfx+Am + AB  0,625 μg/ml 0 0 0 0 0 0 0 0 0 0 
3 group 
1 Control (no preparation) +++ +++ +++ ++ +++ +++ +++ +++ + ++ 
2-8 Н37RV + Н + R + 0 0 0 0 + 0 0 0 0 
4 group 
1 Control (no preparation) ++ ++ +++ +++ ++ ++ +++ +++ + ++ 
2-8 MDR+Mfx+Am + + 0 0 0 +++ ++ 0 0 0 
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Swabs microscopy showed that when cultivating 
MTB for 10, 11, 12, 13 and 14 days, in case of 
ATD and AB availability, MBT was not detected in 
any dilution. During the control (in the third and 
the fourth groups), using only ATD, in case of 10-
day and 11-day incubation periods, MBT in (+, ±) 
was detected, while ATD effect on MBT for 12, 13 
and 14 MBT within microscopic view was not 
detected. There were 10 or more MBT or "obliquity 
formations" within one view when swab 
microscopy was under control.  
When studying the results of the cultural method, 
in control tubes the research scientists recorded the 
growth of MBT colonies of characteristic ivory 
colour with the formation of a structure - like 
braids or plaits. This is typical of microcolonies of 
M. tuberculosis in early periods.  
MBT growth was not detected in the first 
experimental group with the susceptible strain 
H37RV in any test tube into which AB and ATD 
were added (Picture 1).  
 
 
    
 
Picture 1. Growth of H37RV strain surface culture in test tubes with ATD of the first series and 
Alcohol Balsam (B) with 10-day effect on the MBT culture 
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Picture 2. The growth of MDR strain surface culture in test tubes with preparations of the reserve 
series with 10-day effect on the MBT culture 
 
Similar results were obtained in the second group - 
multidrug-resistant strains were supplemented with 
ATD and AB of the second series in the test tubes. 
Somewhat differing results were obtained when 
MBT was supplemented with only ATD of the first 
and second series (third and fourth groups) (Picture 
2). These groups also inhibited the growth of the 
strains studied, but later: in case of susceptible 
strains, this process was observed on day 11, in 
case of multidrug resistant strains - on day 12. 
 
DISCUSSIONS: 
Tuberculosis infection is impossible to control 
successfully without fundamentally new 
approaches to the process of diagnosis and 
treatment. 
Therapy should be based on drugs that have high 
bacteriostatic and bactericidal activity to MBT, a 
wide range of therapeutic effects and normalize the 
immune system. 
However, ATD available in clinics has been used 
for a long time; the range is almost not replenished. 
Those drugs are extremely toxic to the body and 
cause various undesirable side effects. Known 
MBT drug-resistant substances formation can cause 
disease recurrence. 
This is the reason behind the search for new ATD 
actively and directly affecting the TB causative 
agent without any side effects. 
The first step of the problem solution is the 
microbiological research which discovers the 
bacteriostatic and bactericidal activity of new 
drugs, their effectiveness, therapeutic dose and 
terms of treatment, as well as the comparative 
analysis of the antituberculous activity of new 
drugs as compared to the effectiveness of the 
traditional chemotherapeutic drugs. 
The study of new drug combinations activity in in 
vitro experiments is carried out primarily with the 
use of laboratory test strains of human type H37Rv 
M. tuberculosis. In case of evident antibacterial 
activity of substances, the susceptibility of the 
strains isolated from pathological material of TB 
patients shall be studied. Strains susceptible to the 
main ATD and strains with different spectra and 
degree of resistance to them (monostable and MDR 
strains) shall be studied. 
The main factor of MBT pathogenicity is toxic 
glycolipid (cord-factor), located on the surface and 
in the section of a cell wall. According to the 
chemical nature, it is a polymer consisting of a 
single molecule of trehalose disaccharide and 
associated equivalent ratios of mycoli and mycollic 
high-molecular fatty acids, as well as phyto-
cortyldimycerosates. The cord factor has a toxic 
effect on the tissues and insulates MBT against 
phagocytosis, blocking the oxidative 
phosphorylation in the mitochondria of 
macrophages. M. tuberculosis without cord-factor 
is non-pathogenic or slightly pathogenic for 
humans and guinea pigs [8]. 
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MBT virulence shall be  identified by the biological 
samples method and the cord-factor detention by 
means of cytochemical reactions based on the 
property of virulent MBT (with a cord-factor) to 
use dyes firmly (neutral red or Nile blue) and retain 
the colour when alkali is added. The solution and 
non-virulence MBT change their colour [8, p. 549]. 
Staining the clinic isolate of M. tuberculosis 
attenuated in laboratory conditions and MBT non-
pathogenic for various guinea pigs isolated from 
the environment with a neutral red colour has a 
negative reaction. Lipid analysis showed that MBT 
has lost the ability to synthesize phyto-
cortyldimycerosates and other branched-chain cell 
lipids, which are the main factors of M. 
tuberculosis virulence, especially at an early stage 
of infection. Thus, the negative reaction during 
staining is a marker of virulence, indicating 
important disorders of the M.tuberculosis 
membrane and its drugs resistance decrease [30]. 
When staining according to the Ziehl-Neelsen 
method, MBT also retains the original red colour, 
which allows differentiating it from some 
nonpathogenic MBT [8]. 
Virulent strain of M.tuberculosis treated with 
lipidolytic enzymes of G. melonella larvae 
becomes less acid-fast when Tsilu-Nielsen stained, 
and neutral red staining has a negative reaction, 
which indicates the influence of GML preparations 
on the MBT shell. At the same time, the progress of 
MBT stops or slows down, because they 
temporarily lose their virulence, as shown by 
biological tests on guinea pigs [45]. 
The research scientists of the article offered to test 
"Alcohol Balsam" based on bee-keeping products. 
According to the results of the studies in vitro 
experiments (on the breeding ground) it was proved 
that AB at any concentration enhances the 
bactericidal action of traditional ATD and achieves 
100% cessation of culture growth of drug-
susceptible and multiresistant MBT strains at an 
earlier time than in case of ATD application alone. 
According to the results of the current research and 
the above literature data, the following conclusions 
were made: the effect of synergism caused by the 
combined application of ATD and AB was found 
out. AB reduces the resistance of pathogen, 
changing the composition and structure of the 
protective layer of the MBT shell. MBT becomes 
vulnerable after GML treatment and dies faster 
under ATD effect, which justifies the results of the 
studies. 
Thus, the effectiveness and expediency of drugs 
based on GM larvae application for the prevention 
and combined therapy of human tuberculosis have 
been proved. 
It is not possible to make a comparative analysis of 
the experimental results obtained with analogous 
results since such studies were conducted for the 
first time. 
CONCLUSIONS: 
In vitro experimental study of "alcohol balsam" on 
the basis of beekeeping products and the museum 
and multidrug resistant M. tuberculosis strain 
yielded the following results: 
1. 100% cessation of cultures growth of 
MBT drug-susceptible and multidrug-resistant 
strains has been achieved both with the combined 
use of the main ATD and "Alcohol Balsam" with 
the use of anti-tuberculosis drugs only. 
2. In case of the combined use of the main 
ATD and "Alcohol Balsam", cessation of cultures 
growth of mycobacterium tuberculosis drug-
susceptible and multidrug-resistant strains was 
achieved at an earlier time than with the use of 
ATD only. 
The application of ATD in combination with 
AB provides a higher overall antituberculosis effect 
than each of them does separately. 
Thus, the study showed that various 
dilutions of ‘Alcohol balsam’ based on beekeeping 
products being added to the nutrient medium of 
ATD increase their drugs bactericidal effects. 
Moreover, in earlier phases they suppress the 
growth of drug-sensitive and multidrug-resistant 
strains of tuberculosis mycobacterium in 100 % of 
cases. The ATD application alone also had a good 
result, but at a later period of exposure. 
Therefore, the preparations based on 
unconventional beekeeping products, including the 
GM larvae, can be used in prevention and treatment 
of human tuberculosis. 
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